Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121704 | 0.77 | PDPK1 (0.43) | PDPK1IDO1 | |
| SCHEMBL1970744 | 0.74 | IDO1 (0.41) | PDPK1IDO1 | |
| SCHEMBL7214849 | 0.73 | HTR2A (0.40) | KDM1A | |
| SCHEMBL5256851 | 0.72 | PDPK1 (0.39) | PDPK1IDO1 | |
| SCHEMBL14990217 | 0.70 | — | — | |
| SCHEMBL435482 | 0.70 | — | — | |
| SCHEMBL316316 | 0.67 | SRD5A1 (0.41) | PDPK1IDO1 | |
| SCHEMBL8332242 | 0.67 | KDM4E (0.31) | — | |
| SCHEMBL290887 | 0.66 | HTR2A (0.39) | IDO1 | |
| SCHEMBL7980704 | 0.66 | PRCP (0.39) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4800216-B2 | — | — | 2011-10-26 | — | — | JP | claimed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | claimed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | claimed |
| JP-2007527413-A | — | — | 2007-09-27 | — | — | JP | claimed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | claimed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | claimed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | claimed |
| US-11219616-B2 | Dosing regimens of celgosivir for the treatment of dengue | 60 Degrees Pharmaceuticals, LLC (US) | 2022-01-11 | — | — | US | disclosed |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-1987037-A2 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2008-11-05 | — | — | EP | disclosed |
| EP-1678168-A4 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2007097470-A2 | FUSED NITROGEN- COMPRISING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-08-30 | — | — | WO | disclosed |
| EP-1678168-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | Exelixis, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005039506-A2 | P70S6 KINASE MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2005-05-06 | — | — | WO | disclosed |
| US-5750558-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS | ABBOTT LABORATORIES (US) | 1998-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11219616-B2 | Dosing regimens of celgosivir for the treatment of dengue | F3, DPP4, C5 | PDPK1 2556/4885KDM1A 648/4885MAOA 2697/4885 |
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | PDPK1 20/4885KDM1A 3520/4885MAOA 4304/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | PDPK1 20/4885KDM1A 3520/4885MAOA 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.